drugset / Trial / NCT01545648
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Phase 2
Terminated
4 enrolled
Hope Rugo, MD
Amgen · collabUniversity of California, San Francisco · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether taking denosumab for 12 months in women with a significant number of disseminated tumor cells in the bone marrow can reduce the number of these cells below a significant level.
Timeline
- Start
- 2012-11-01
- Primary completion
- 2015-06-09
- Completion
- 2016-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |